FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Kisqali Expanded Approval for Early Breast Cancer

[ Price : $8.95]

FDA approves an expanded use for Novartis Kisqali (ribociclib) combination use with an aromatase inhibitor for the adjuvant treat...

FDA Lifts Partial Clinical Hold on Alzheimers Drug

[ Price : $8.95]

FDA lifts a partial clinical hold against Vigil Neuroscience and its ongoing Phase 1 clinical trial of VG-3927, a small molecule t...

CGMP Violations at Italian Drug Plan

[ Price : $8.95]

In an untitled letter, FDA says Milan, Italy-based Industria Farmaceutica is manufacturing drugs with CGMP violations.

FDA Extends Treosulfan NDA Review by 3 Months

[ Price : $8.95]

Medexus Pharmaceuticals says FDA has extended the review of its Medac licensors resubmitted NDA for treosulfan and its use in allo...

SSM St. Clare Health Gets FDA-483

[ Price : $8.95]

FDA issues SSM St. Clare Health Center a 10-observation Form FDA-483 for GMP deficiencies found during an inspection at an outsour...

Guide on Oncology Multiregional Clinical Trials

[ Price : $8.95]

FDA posts a draft guidance entitled Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Developme...

3 De Novo Device Classifications

[ Price : $8.95]

Federal Register notices: FDA classifies three devices into Class 2 based on de novo classification requests Saladax Biomedicals ...

CVM Draft Guide on CMC Technical Section

[ Price : $8.95]

FDA releases a CVM draft guidance entitled Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies.

Apple Watch Cleared for Assessing Sleep Apnea

[ Price : $8.95]

FDA clears an Apple 510(k) for its Apple Watch to be used as an over-the-counter device for assessing the risk of sleep apnea.

Boehringer Ingelheim Plans Pulmonatry Fibrosis NDA

[ Price : $8.95]

Boehringer Ingelheim plans an NDA for nerandomilast for treating idiopathic pulmonary fibrosis (IPF) after reporting that its Phas...